Full Press Release Details
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) has announced the recipients of the Linked by Lupus: Optimal Care Initiative grant, awarding nearly $1 million to support national, state, and local non-profit organizations working to improve the lives of people impacted by lupus, including systemic lupus erythematosus (SLE) and lupus nephritis (LN).
GSK previously sought proposals for community-driven initiatives aimed at improving earlier diagnosis and recognition of lupus signs and symptoms; enhancing awareness of and access to evidence-based treatment options; and/or advancing communication between patients and providers regarding lupus.
“We’re proud to support these organizations that are deeply embedded in their communities and uniquely positioned to drive meaningful change,”Court Horncastle, Senior Vice President at GSK, said. “Their work is essential to improving the lupus journey, from diagnosis to treatment to ongoing care, and we’re honored to help bring their visions to life.”
Launched inJune 2025, the Linked by Lupus: Optimal Care Initiative is part of GSK’s ongoing commitment to improving outcomes for people living with lupus. These efforts align with the initiative’s mission to foster a more connected, informed, and supported lupus community. The selected organizations include 13 grantees from across the country, chosen for their innovative, community-led programs designed to improve earlier diagnosis, enhance awareness of and access to evidence-based treatment, and advance communication between patients and providers.
The 2025 Linked by Lupus grant recipients include:
Anne Marie Blacketer, CFRE, CEO of Lupus Texas Gulf Coast, an independent, locally based chapter of the Lupus Foundation of America, takes her lead from the community. Blacketer said, “We listened closely as members shared their need for greater education and awareness about lupus, including how to access the high-quality healthcare they deserve. From diagnostic testing and physicians who truly understand the disease to learning about and obtaining impactful treatments—these are the resources and support we work to provide to individuals and their health partners.”
As this work moves forward, GSK remains committed to supporting initiatives that strengthen and uplift lupus communities nationwide. These investments represent only one step in a long-term effort to advance meaningful change, expand access to resources, and empower those affected by lupus.
More information about future funding opportunities is availablehere.
About GSKGSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more atgsk.com.
Cautionary statement regarding forward-looking statementsGSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the “Risk Factors” section in GSK’s Annual Report on Form 20-F for 2024, and GSK’s Q3 Results for 2025.
Registered in England & Wales:No. 3888792
Registered Office:79 New Oxford StreetLondonWC1A 1DG
GSK inquiriesMediaKathleen Quinn, +1 202 603 5003 (Washington DC)Lyndsay Meyer, +1 202 302 4595 (Washington DC)Investor Relations:Jeff McLaughlin, +1 215 751 7002 (Philadelphia)Frannie DeFranco, +1 215 751 3126 (Philadelphia)